Lucid Diagnostics Inc (LUCD)vsNovartis AG ADR (NVS)
LUCD
Lucid Diagnostics Inc
$0.54
-10.38%
HEALTHCARE · Cap: $121.83M
NVS
Novartis AG ADR
$142.41
+3.14%
HEALTHCARE · Cap: $267.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1041094% more annual revenue ($56.69B vs $5.45M). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
LUCD
Avoid24
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LUCD.
Margin of Safety
-53.2%
Fair Value
$93.54
Current Price
$142.41
$48.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 26.7% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Trading at 9.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LUCD
The strongest argument for LUCD centers on Revenue Growth. Revenue growth of 26.7% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : LUCD
The primary concerns for LUCD are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.28 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
LUCD profiles as a growth stock while NVS is a value play — different risk/reward profiles.
LUCD carries more volatility with a beta of 1.12 — expect wider price swings.
LUCD is growing revenue faster at 26.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 24/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lucid Diagnostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Lucid Diagnostics Inc. is a commercial stage medical diagnostic technology company. The company is headquartered in New York, New York.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?